What is GlucoTrack?
GlucoTrack, Inc. operates at the intersection of medical technology and patient-centric healthcare, specializing in the design and development of non-invasive monitoring systems. The company's flagship product, GlucoTrack, addresses a critical pain point for the diabetic and pre-diabetic population by eliminating the need for traditional, invasive blood-sampling methods. By leveraging advanced sensor technology, the firm provides a seamless, user-friendly alternative that enhances patient compliance and long-term health outcomes. Positioned within the competitive landscape of digital health and diagnostic devices, GlucoTrack, Inc. is carving out a niche by prioritizing clinical efficacy alongside user experience, effectively bridging the gap between laboratory-grade accuracy and daily consumer convenience.
How much funding has GlucoTrack raised?
GlucoTrack has raised a total of $25.6M across 3 funding rounds:
Other Financing Round
$100K
Private Equity
$20M
Debt
$5.5M
Other Financing Round (2024): $100K, investors not publicly disclosed
Private Equity (2025): $20M led by Sixth Borough Capital Management
Debt (2026): $5.5M, investors not publicly disclosed
Key Investors in GlucoTrack
Sixth Borough Capital Management
Sixth Borough Capital Management is a multi-stage, event-driven alternative investment manager that focuses on small and mid-cap private and public equities, with a strong interest in healthcare and technology innovation.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for GlucoTrack?
With the recent influx of capital, GlucoTrack, Inc. is well-positioned to scale its manufacturing capabilities and expand its market footprint across the United States. The strategic focus will likely shift toward optimizing supply chain logistics and deepening clinical validation to support broader insurance reimbursement pathways. As the company moves beyond its development phase, the integration of this latest financing will be pivotal in sustaining its competitive advantage against established incumbents. Future growth trajectories will depend on the firm's ability to maintain its technological edge while navigating the stringent regulatory requirements inherent in the medical device sector. Investors and stakeholders will be closely monitoring the company's progress in achieving mass-market adoption and its ability to leverage this debt-based financing to drive sustainable, long-term value creation in the diabetes care market.
See full GlucoTrack company page
